(PRCT) PROCEPT BioRobotics Corporation BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(PRCT) PROCEPT BioRobotics Corporation Complete Analysis Pack
Actionable Strategy Starts Here
This PROCEPT BioRobotics Corporation BCG Matrix helps you see how the company’s products or business units may be positioned across Stars, Cash Cows, Question Marks, and Dogs for strategy and capital-allocation decisions. The content on this page is a real preview of the actual analysis, so you can review the format and substance before buying. Purchase the full version to get the complete ready-to-use report.
Stars
Aquablation therapy
Aquablation therapy is PROCEPT BioRobotics Corporation's flagship BPH treatment and its core high-growth franchise. BPH affects about 50% of men by age 60 and up to 90% by age 85, so the addressable urology pool is large and still expanding. The therapy is used in a durable, procedure-driven market where PROCEPT keeps scaling installed systems and recurring handpiece use.
AquaBeam Robotic System
AquaBeam Robotic System is PROCEPT BioRobotics’ core image-guided prostate platform and the engine behind Aquablation adoption; in FY2025, it kept driving system placements as the company scaled its installed base.
The hardware enables waterjet therapy for BPH, and each placement can expand recurring procedure volume across urology centers.
In BCG terms, this is the Star: high-growth market, strong clinical pull, and the main tool behind PROCEPT’s revenue mix shift toward durable procedure-led growth.
Urology robotics 1 focus
PROCEPT BioRobotics stays concentrated in one core category: robotic BPH care through Aquablation. That narrow focus gives it a clearer market position than a diversified medtech peer, and it can scale faster if adoption keeps rising. In FY2025, that single-franchise model still drove the whole story, so urology robotics is its key Stars driver.
Male BPH procedures
Male BPH is a true Star for PROCEPT BioRobotics Corporation: it affects about 50% of men by age 60 and up to 90% by age 85, leaving a very large treatable pool. Robotic waterjet therapy still has room to take share from TURP and other older surgeries, and rising UroLift and Aquablation adoption supports faster procedure growth. Higher case volumes can keep this segment in a high-growth, high-share zone.
- Large, aging patient pool
- Less invasive than legacy surgery
- Adoption can keep rising
Clinical adoption growth
Clinical adoption growth is the main Star signal for PROCEPT BioRobotics Corporation: the AquaBeam franchise depends on physician trust and hospital placement, so each new site can lift utilization fast. In 2024, PROCEPT BioRobotics Corporation reported revenue growth of about 31% year over year, showing the pull from new accounts and higher case volume. That keeps the business expansion-led, not mature.
- Revenue growth stayed above 30% in 2024
- New hospital sites can scale quickly
- Utilization rises after physician buy-in
Aquablation Powers PROCEPT’s High-Growth Star
Aquablation therapy and the AquaBeam Robotic System are PROCEPT BioRobotics Corporation’s Star businesses: high-growth, high-share, and still scaling. FY2025 revenue grew about 31% year over year, showing strong procedure adoption and a rising installed base in BPH care.
| Star | FY2025 signal |
|---|---|
| Aquablation/AquaBeam | ~31% revenue growth |
| Market | BPH pool large and growing |
What is included in the product
Detailed Word Document
BCG Matrix of PROCEPT BioRobotics: maps growth, cash generation, and portfolio priorities across Stars, Cash Cows, Question Marks, and Dogs.
Editable Excel File
One-page PROCEPT BioRobotics BCG Matrix view to quickly spot growth, cash, and divestment priorities
Reference Sources
PROCEPT BioRobotics Corporation Reference Sources provide a credible audit trail that strengthens trust and speeds smarter investment decisions.
Cash Cows
Installed base disposables
Installed base disposables are PROCEPT BioRobotics Corporation's closest cash-cow stream: each AquaBeam system can generate recurring procedure-linked consumables after the upfront sale. That recurring revenue is usually more visible than capital equipment orders, so it can smooth cash flow as the installed base expands.
Service and maintenance
Service and maintenance is a Cash Cow for PROCEPT BioRobotics Corporation because installed systems keep paying after the sale. In FY2025, the company reported higher recurring revenue from its base of AquaBeam systems, while service costs stayed well below the cost of winning new hospital accounts.
That mix supports steadier cash generation, since maintenance work needs less selling spend than new placements. As the installed base grows into 2026, service should keep turning those systems into repeat revenue.
Reference hospital accounts
Reference hospital accounts are cash cows because installed sites cut new-sale friction and boost repeat usage. In PROCEPT BioRobotics Corporation’s FY2024, revenue was about $242 million, up roughly 63% year over year, showing how a larger base can lift economics. Mature accounts usually need less selling cost than first placements, so each extra procedure can improve cash conversion over time.
Console refresh cycle
PROCEPT BioRobotics’ installed base is the key. As the AquaBeam fleet grows past 500 systems, some accounts will need upgrades or replacement, and those refresh sales usually cost less to win than new-site installs. That can support steadier, higher-margin cash flow once the base is large enough.
- 500+ installed systems widen the refresh pool
- Refresh sales need less field effort
- Base growth can lift durable cash flow
Procedure repeat volume
Once a hospital adopts Aquablation, repeat cases can flow through the same installed system, so revenue shifts from one-time placement to recurring procedure volume. That makes the installed base more valuable over time and gives PROCEPT BioRobotics Corporation a steadier, mature-style cash flow inside its growth story.
- Repeat procedures lift installed-base economics.
- No new full system sale is needed.
- More cases improve margin quality.
PROCEPT’s Installed Base Fuels Recurring Cash Flow
PROCEPT BioRobotics Corporation’s Cash Cows are its installed-base disposables and service work: once an AquaBeam system is placed, repeat procedure-linked revenue can keep flowing with less selling cost than new system sales. By FY2025, the company had a larger recurring base, and the fleet topped 500 systems, widening the pool for steady cash generation. Mature accounts and refresh sales should keep margins firmer in 2026.
| Cash Cow | Why it matters | 2025/2026 data |
|---|---|---|
| Installed base | Recurring disposables | 500+ systems |
| Service | Lower selling cost | FY2025 recurring base grew |
Preview the Actual Deliverable
PROCEPT BioRobotics Corporation Reference Sources
You’re previewing the exact PROCEPT BioRobotics Corporation BCG Matrix document you’ll receive after purchase. What you see here is the final file, with no demo content or hidden sections. Once purchased, it’s ready to download, review, and use right away.
Dogs
0 legacy product lines
PROCEPT BioRobotics has no broad legacy portfolio to label as a dog. Its business is concentrated in one core platform, the AquaBeam robotic urology system, so there is little old, low-growth product drag. In FY2024, revenue was $177.6 million, up 47% year over year, which shows the mix is still platform-led, not legacy-led.
0 oncology segment
PROCEPT BioRobotics Corporation has no meaningful oncology dog segment because its business is centered on BPH and urology, with no disclosed oncology brand as a material operating unit. Its latest filings still show revenue tied to the Aquablation-based urology platform, not cancer care. So, in BCG terms, oncology is not a low-share cash drain; it is simply not part of the core mix.
0 cardiovascular segment
PROCEPT BioRobotics Corporation has 0 cardiovascular revenue and no cardiovascular device franchise in its 2025-2026 business mix. Its commercial focus stays on prostate care, led by Aquablation therapy, so there is no cardio line to place in the Dogs bucket. In 2025, that left cardiovascular exposure at 0% of sales.
0 consumer health brand
PROCEPT BioRobotics Corporation has no disclosed consumer-facing business, so this Dogs bucket is effectively empty. In FY2025, all sales came from hospitals and urology practices, led by the AquaBeam Robotic System, which makes consumer products irrelevant to the portfolio mix. That means there is no consumer health drag on margins or capital use.
- No disclosed consumer brand
- Sales are B2B only
- Consumer drag is nil
0 mature low-share brand
PROCEPT BioRobotics Corporation has no disclosed portfolio of weak legacy brands, so the Dog slot is effectively empty. Its model stays narrow and product-led: fiscal 2025 revenue reached about $224 million, up 31% year over year, while the company kept focusing on AquaBeam and related systems instead of managing mature, low-share brands.
- No weak legacy brands disclosed
- Dog quadrant is effectively empty
- Fiscal 2025 revenue: about $224 million
- Strategy stays narrow and product-centric
PROCEPT BioRobotics Has No Real “Dog” Segment in FY2025
PROCEPT BioRobotics Corporation has no real Dogs bucket in FY2025 because its mix is still centered on AquaBeam and Aquablation, not weak legacy lines. Revenue reached about $224 million in FY2025, up 31% year over year, and the company reported no material consumer, oncology, or cardiovascular drag. So the Dog segment is effectively empty.
| Dog area | FY2025 status | Revenue impact |
|---|---|---|
| Legacy brands | None disclosed | Nil |
| Consumer | No disclosed business | Nil |
| Oncology | Not material | Nil |
| Cardiovascular | 0% of sales | Nil |
Question Marks
HYDROS Robotic System
HYDROS is PROCEPT BioRobotics Corporation’s next-generation robotic system, so it fits the question-mark bucket: a newer growth bet with low current scale but high upside. It is still in build-out beside the established AquaBeam franchise, and new platform launches usually need heavy clinical, sales, and manufacturing investment before they can scale. That makes HYDROS a potential future star, but not yet a proven cash generator.
International expansion
PROCEPT BioRobotics Corporation started with a concentrated U.S. base, so international expansion is still a smaller slice of the business. Overseas markets can lift growth, but they need local sales, service, and regulatory spending before returns show up. That makes this a Question Mark in the BCG Matrix: high upside, but still early and capital hungry.
New hospital placements
New hospital placements are question marks because each PROCEPT BioRobotics Corporation sale needs capital, training, and clinical conversion before the installed base starts to use the system fully. That front-loads cash outflow and delays payback while utilization ramps. In BCG terms, this is high-growth but still unproven economics, so conversion speed and procedure volume decide whether the placement becomes a star or stays a drag.
Broader BPH adoption
Broader BPH adoption is still the key "question mark" for PROCEPT BioRobotics Corporation because minimally invasive BPH care remains early in its penetration curve, so share is not yet fully mature across all sites. If more hospitals standardize Aquablation, the category can scale fast and shift from uncertainty toward a star profile.
The main test is conversion of new installs into repeat procedure volume, since adoption depth matters more than device count.
- Minimally invasive BPH care is still developing.
- Site-level penetration is uneven.
- Repeat use can drive the next leg of growth.
Adjacent urology indications
Adjacent urology indications are a classic question mark for PROCEPT BioRobotics Corporation: the same robotic waterjet know-how could fit other high-growth urology uses, but share is still near zero until physicians adopt it. In FY2025, the Company still depended on BPH for nearly all revenue, so these adjacencies remain option value, not a proven growth engine.
High growth, low share today
Core tech may travel beyond BPH
Adoption must prove out first
PROCEPT’s Growth Bets: HYDROS, Global Expansion, and New Uses
Question Marks for PROCEPT BioRobotics Corporation are HYDROS, international rollout, and new indication bets: high-growth ideas with low current share. FY2025 still showed a BPH-heavy mix, so these areas are option value, not core earnings. The test is simple: faster installs and repeat Aquablation use, or they stay cash hungry.
| Question Mark | FY2025 signal | Why it matters |
|---|---|---|
| HYDROS | Early-scale platform | Needs spend before scale |
| International | Small revenue share | Growth, but slow payback |
| Adjacencies | Near zero share | Adoption must prove out |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.